Natália Maria Valeriano da Silva

Natália Maria Valeriano da Silva

Auto-generated profile, based on publicly available information

Natália Maria Valeriano da Silva


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2026 in Revista ft
Verified
Journal Article
Open access
LBLaysla Tamyres de Oliveira Borges
Laysla Tamyres de Oliveira Borges
POPaulo José de Andrade Lira Oliveira
Paulo José de Andrade Lira Oliveira
NSNatália Maria Valeriano da Silva
Natália Maria Valeriano da Silva
MOMaria Clara Gomes Oliveira
Maria Clara Gomes Oliveira
RTRafael Ramos Teles
Rafael Ramos Teles
MSMilena Marcia da Silva
Milena Marcia da Silva
Introduction: liquid biopsy, through the analysis of circulating tumor DNA (ctDNA), has become established in precision oncology as a tool to detect molecular residual disease and predict recurrence in solid tumors. Objective: to review recent advances in the use of ctDNA during follow-up after curative-intent treatment, highlighting clinical applications, therapeutic implications and current limitations. Methods: narrative literature review with a structured search strategy in PubMed/MEDLINE, SciELO and Google Scholar, using DeCS and MeSH descriptors combined with Boolean operators, covering 2021 to 2026; after screening of titles, abstracts and full texts, nine studies made up the final sample. Results: ctDNA detection after curative treatment identifies high-risk patients before radiological progression, with the most consistent evidence in colorectal cancer and promising results in breast cancer, non-small cell lung cancer and melanoma. Tumor-informed and tumor-agnostic approaches support risk stratification and individualized therapeutic decisions, including escalation and de-escalation of adjuvant therapy. However, analytical and clinical challenges remain, such as false-positive results caused by clonal hematopoiesis, reduced sensitivity at certain anatomical sites, lack of standardized protocols and high cost. Conclusion: ctDNA is a promising biomarker for the early detection of molecular residual disease and recurrence prediction, supporting personalized cancer care; nevertheless, its broad clinical adoption depends on further prospective validation, methodological standardization and cost reduction.